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CLINICIAN REPORTED OUTCOMES: ISSUES IN THE TRANSLATION 
AND LINGUISTIC VALIDATION
Furtado T, Wild D
Oxford Outcomes Ltd, Oxford, Oxon, UK
OBJECTIVES: The use of Clinician Reported Outcomes (ClinROs) and cognitive 
functioning measures in multi-national clinical trials is widespread, but the translation 
of such measures has often been avoided, with trial managers preferring to keep the 
measures in English. However, this approach is not ideal and recently the importance 
of translating and linguistically validating ClinROs has been highlighted. The require-
ments for translating and linguistically validating ClinROs have not been well docu-
mented. Usually, they are translated with a PRO translation procedure (comprising 
dual forward and back translations and subsequent review) with the addition of a 
single clinician review. This study investigates the issues surrounding the translation 
and linguistic validation of these ClinROs and cognitive functioning measures. 
METHODS: A review was undertaken of translation reports from past projects, 
including the MMSE and SCID (cognitive functioning measures), TNSN (clinician or 
nurse guide for assessing neuropathy) 6 Minute Walk Test (6MWT) Worksheet, (guide 
for clinicians to assess dyspnoea), and EORTC clinician scales. Examples of issues 
from the translation process were gathered. RESULTS: Clinical review as part of the 
translation process proved invaluable. Changes typically comprised alterations of 
speciﬁ c terminology.—a clinician should also be available to aid project coordinators 
throughout the translation process.—Clinical review formed an essential role for 
advising lead translators.—One project included dual clinician reviews; this was par-
ticularly valuable since changes could be veriﬁ ed between reviewers. CONCLUSIONS: 
The translation and linguistic validation of ClinROs and cognitive functioning mea-
sures requires further research to determine the optimum methodology. This study 
found that clinical review was of the utmost importance, and that ideally dual clinician 
reviewers should be involved. Furthermore, translators should have experience of 
translating documents intended for clinical use, to ensure they are familiar with the 
terminology.
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USING DOZENS OF ATTRIBUTES WITHOUT INCREASING 
RESPONDENT BURDEN: HOW TO ADAPT LATENT VARIABLE 
MODELING FOR LINKING ATTRIBUTES ON SEPARATE CONJOINT 
SURVEYS
Cole JC1, Dang J2
1Covance Market Access Services, San Diego, CA, USA; 2University of California, Los 
Angeles, Torrance, CA, USA
Conjoint analysis is a rigorous survey technique used to understand health care prefer-
ences in the pharmaceutical and medical device industries. In a traditional conjoint 
study, respondents are presented with a complete proﬁ le of all of the combination of 
attributes and features (or levels) for a particular product or service. However, 
research involving a large number of attributes can be too burdensome for respondents 
and has been shown to elicit inaccurate responses. This study describes a procedure 
used to link attributes from two or more different conjoint surveys that share at least 
one attribute. Linked latent conjoint modeling can lessen the burden on respondents 
while allowing utility parameters to be estimated for a large number of attributes, all 
on the same interval scale. Conjoint survey data were linked using a partial proﬁ le 
design and parameters were calculated using maximum likelihood estimation for ﬁ nite 
mixture modeling. Several examples demonstrating the procedures used to link choice 
based survey data are provided. In addition, results from a latent variable modeling 
of the linked survey data are reviewed. Finally, to illustrate the ﬂ exibility of latent 
conjoint analysis, continuous and categorical covariates were simultaneously esti-
mated to demonstrate the usefulness of latent modeling of conjoint data.
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COGNITIVE DEBRIEFING METHODS IN TRANSLATION OF PROS: A 
MULTI-NATIONAL
Furtado T, Gergovich KB, Wild D
Oxford Outcomes Ltd, Oxford, Oxon, UK
OBJECTIVES: Cognitive debrieﬁ ng interviews are a key component of the translation 
and linguistic validation of PROs and a necessity when a PRO is to be used as a 
primary or secondary endpoint for an FDA label claim. The 2005 ISPOR principles 
of good practice report describes the objectives of debrieﬁ ng, but little discussion has 
been undertaken into the methods for performing debrieﬁ ng interviews as part of the 
translation and linguistic validation process. This abstract presents a pilot test of 
methodologies across countries. METHODS: A literature review was conducted on 
cognitive debrieﬁ ng methodology, and different approaches were pilot tested in 10 
countries. Three methodologies were selected for pilot testing: 1) Retrospective 
probing 2) Retrospective think aloud 3) Concurrent think aloud. RESULTS: The lit-
erature review highlighted the methodologies and pros and cons of different 
approaches to cognitive debrieﬁ ng, but no research was identiﬁ ed that addressed the 
issues of particular relevance in the translation and linguistic validation process. All 
three processes listed above proved suitable for a methodology for linguistic valida-
tion. The Think Aloud technique provided a true sense of the respondent’s understand-
ing of the translation but its suitability was particularly subject to cultural and 
individual differences. Questionnaires of a personal nature (e.g. those pertaining to 
sex or bowel disorders) beneﬁ ted from Retrospective Probing, since the patients could 
respond hypothetically. The Retrospective Think Aloud technique elicited more infor-
mation from some respondents, since it allowed them to discuss their personal experi-
ence. Where the respondent had difﬁ culty in understanding what was required of 
them, modifying the interview style proved beneﬁ cial. CONCLUSIONS: A combina-
tion of Retrospective Probing and Retrospective Think Aloud proved to be the 
optimum methodology across countries, but this was dependent on the culture, 
patient, and the nature of the PRO being translated.
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CONSTRUCTION OF PRIMARY HUI3 PERSON-MEAN UTILITY SCORING 
FUNCTION
Furlong W1, Feeny D2, Torrance G3
1Health Utilities Inc., Dundas, ON, Canada; 2Kaiser Permanente Center for Health Research, 
Portland, OR, USA; 3McMaster University, Toronto, ON, Canada
OBJECTIVES: To assess construction of the primary HUI3 scoring system. 
METHODS: Mean visual analogue scale (VAS) and standard gamble (SG) scores were 
collected in 2 face-to-face interview surveys: modeling survey (MS) for the Person-
Mean utility scoring model to calculate community utilities for health states; direct 
survey (DS) for validation of the Person-Mean scoring model. Survey results are 
assessed for completeness and consistency. Completeness is evaluated by response 
rates and consistency by health state rankings. RESULTS: Completed interviews were 
obtained from 65% of contacted eligible subjects. Demographic distributions are 
similar to the underlying general population. There are 256 respondents in MS and 
248 in DS. MS and DS respondents use 71% of HUI3 attribute levels in describing 
their own health status. Each of the 8 HUI3 attributes are reported by 35 or more 
respondents as being important in their preference measurements: pain (49%); vision 
(37%); cognition (34%); emotion (28%); ambulation (28%); hearing (17%); dexterity 
(17%); speech (7%). More than 70% of respondents focused on 2+ attributes. Other 
important preference measurement factors are self-care ability (89% of respondents), 
family life (76%), happiness of others (69%), ability to work current job (61%), 
leisure activities (42%). 83% of respondents report the interviewing did not change 
their opinions about the health states. Consistency of health state rankings by mean 
VAS and SG scores between MS and DS was 100%: PH > MA > MB > MC > Dead 
> Pits. MS had a missing data rate of 0.29% (17/5920) for VAS and 0.10% (1/1024) 
for SG. CONCLUSIONS: The Person-Mean HUI3 utility function is founded on a 
survey that was well-constructed in terms of community and attribute representation, 
consideration of multiple attributes and day-to-day impacts, stable opinions, and 
consistency of health state rankings. This evidence supports use of the primary HUI3 
utility function for group-level analyses, such as allocation of societal resources.
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MINIMALLY IMPORTANT DIFFERENCE OF THE TREATMENT 
SATISFACTION WITH MEDICINES QUESTIONNAIRE (SATMED-Q)
Rejas J1, Ruiz MA2, Pardo A2, Soto J1
1Pﬁ zer España, Alcobendas/Madrid, Spain; 2Universidad Autonoma de Madrid, Madrid, Spain
OBJECTIVES: Treatment satisfaction with drug therapies is an important patient-
reported-outcome (PRO) that may help clinicians to better impact in patient health 
care. The Treatment Satisfaction with Medicines (SATMED-Q) questionnaire has 
shown appropriate psychometric properties for exploring patient’s satisfaction with 
medicines under routine medical practice in chronic health conditions. The Minimally 
Important Difference (MID) of the instrument is still unknown. The goal of this 
research was to determine the MID values of the SATMED-Q questionnaire for the 
total score and domains. METHODS: The sample of patients (457, mean age 59 years, 
53% male) used for testing psychometric properties was also used to assess MID 
values. Item #14 of the TSQM scale was used as an anchor reference, since it explores 
directly the satisfaction with medicines in a seven points ordinal response (from 
extremely satisﬁ ed to extremely dissatisﬁ ed). Patients were classiﬁ ed into four catego-
ries according with responses in this item; extremely satisﬁ ed/dissatisﬁ ed, very satis-
ﬁ ed/dissatisﬁ ed, satisﬁ ed/dissatisﬁ ed, nor satisﬁ ed/nor dissatisﬁ ed and comparisons 
were carried out for the overall score and each domain of the SATMED-Q using 
standardized scores. The mean differences in overall score (and domains) between the 
neutral category and the satisﬁ ed/dissatisﬁ ed category were considered the values of 
MID. Effect sizes (ES) were also computed. RESULTS: MID for total scoring was 13.4 
(ES = 0.91), while the value for domains ranged from 10.3 (medical care domain, ES 
= 0.43) to 20.6 (impact of daily living, ES = 0.85). Mean score differences in overall 
scale and domains were signiﬁ cant between change in satisfaction categories with 
respect item#14 with F values ranging from 9.7 to 74.1 (P < 0.001 in all cases). 
CONCLUSIONS: The SATMED-Q demonstrated to be responsive to different levels 
of patient’s satisfaction with therapy in chronically ill subjects. Attained MID was 
13.4 pts for the overall normalized scoring scale and between 10.3 and 20.6 pts for 
domains.
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ESTIMATING HEALTH STATE UTILITY VALUES FOR COMORBID 
HEALTH CONDITIONS
Ara R, Brazier J
University of Shefﬁ eld, Shefﬁ eld, UK
OBJECTIVES: Health state utility values (HSUVs) for comorbid health conditions 
(CHC) are frequently estimated using data from single health conditions but there is 
no consensus on the most appropriate method. The objective of the study is to compar-
ing ﬁ ve techniques in a single data set. METHODS: We use EQ-5D data from the 
Health Survey for England to compare results generated using the: additive, multiplica-
tive and minimum methods, the adjusted decrement estimator (ADE), and a linear 
regression model; a baseline of perfect health and an adjusted baseline obtained from 
